Artesunate: A potential drug for the prevention and treatment from hepatitis to hepatocellular carcinoma

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064 · see citing works

Burden of liver diseases in the world

Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783 · see citing works

The Traditional Medicine and Modern Medicine from Natural Products

Yuan, H.-D., Ma, Q., Li, Y., & Piao, G. (2016) · Molecules · doi:10.3390/molecules21050559 · Cited by 2,451 · see citing works

Techniques for extraction and isolation of natural products: A comprehensive review

Zhang, Q.-W., Lin, L.-G., & Ye, W.-C. (2018) · Chinese Medicine · doi:10.1186/s13020-018-0177-x · Cited by 2,321 · see citing works

AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052 · see citing works

Senescence of activated stellate cells limits liver fibrosis

Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.06.049 · Cited by 2,029 · see citing works

Senescence of Activated Stellate Cells Limits Liver Fibrosis

Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027

Liver cirrhosis

Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663 · see citing works

Mechanisms of HBV-induced hepatocellular carcinoma.

Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,008 · see citing works

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 804 · see citing works

Hepatic inflammatory responses in liver fibrosis

Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803 · see citing works

Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis

Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671 · see citing works

Global, regional and national burden of primary liver cancer by subtype

Rumgay, H., Ferlay, J., de Martel, C., Georges, D., Ibrahim, A. S., Zheng, R., Wei, W., Lemmens, V. E. P. P., & Soerjomataram, I. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.023 · Cited by 615 · see citing works

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 505 · see citing works

The role of IL-6/JAK2/STAT3 signaling pathway in cancers

Huang, B., Lang, X., & Li, X.-H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023177 · Cited by 465 · see citing works

Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets

Yang, Y. M., Kim, S., & Seki, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1676806 · Cited by 453 · see citing works

Fibrosis-dependent mechanisms of hepatocarcinogenesis

Zhang, D. Y., & Friedman, S. L. (2012) · Hepatology · doi:10.1002/hep.25670 · Cited by 444 · see citing works

Metabolic reprogramming in liver fibrosis

Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432 · see citing works

Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway

Kong, Z., Liu, R., & Cheng, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.030 · Cited by 364 · see citing works

Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation

Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344 · see citing works

Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action

Hou, J., Wang, D., Zhang, R., & Wang, H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0197 · Cited by 319 · see citing works

Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma

Li, Z., Dai, H.-Q., Huang, X., Ji, F., Deng, J.-H., Wang, Z.-X., Yang, X., Liu, Y., Wu, Y., Chen, P.-H., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0478-3 · Cited by 317 · see citing works

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review

Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., & Omata, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061358 · Cited by 258 · see citing works

Cellular Mechanisms of Liver Fibrosis

Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252 · see citing works

Hepatocellular Carcinoma Immunotherapy

Sperandio, R. C., Pestana, R. C., Miyamura, B. V., & Kaseb, A. O. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042220-021121 · Cited by 198 · see citing works

STAT3, a key regulator in liver fibrosis.

Zhao, J., Qi, Y.-F., & Yu, Y.-R. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.06.010 · Cited by 190 · see citing works

Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis

Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189 · see citing works

Epidemiology and Prevention of Hepatitis A in Travelers

Steffen, R. (1994) · JAMA · doi:10.1001/jama.1994.03520110065031 · Cited by 184 · see citing works

Immune suppression in chronic hepatitis B infection associated liver disease: A review

Li, T.-Y., Yang, Y., Zhou, G. F., & Tu, Z. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i27.3527 · Cited by 163 · see citing works

Antimalarial Bioavailability and Disposition of Artesunate in Acute Falciparum Malaria

Newton, P. N., Suputtamongkol, Y., Teja‐Isavadharm, P., Pukrittayakamee, S., Navaratnam, V., Bates, I., & White, N. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.972-977.2000 · Cited by 158 · see citing works

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals

Baumert, T. F., Jühling, F., Ono, A., & Hoshida, Y. (2017) · BMC Medicine · doi:10.1186/s12916-017-0815-7 · Cited by 146 · see citing works

Autophagy and cancer: Modulation of cell death pathways and cancer cell adaptations

Towers, C. G., Wodetzki, D., & Thorburn, A. M. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201909033 · Cited by 139 · see citing works

HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Wang, Y., Zhao, M., Zhao, L., Geng, Y., Li, G., Chen, L., Yu, J., Yuan, H., Zhang, H., Yun, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3169 · Cited by 113 · see citing works

A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies

Deeken, J. F., Wang, H., Hartley, M. L., Cheema, A. K., Smaglo, B. G., Hwang, J. J., He, A. R., Weiner, L. M., Marshall, J. L., Giaccone, G., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3533-8 · Cited by 103 · see citing works

Liver fibrosis and extracellular matrix

Biagini, G., & Ballardini, G. (1989) · Journal of Hepatology · doi:10.1016/0168-8278(89)90170-0 · Cited by 96 · see citing works

Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy

Ma, Z., Chen, W., Liu, Y., Yu, L., Mao, X., Guo, X., Jiang, F., Guo, Q., Lin, N., & Zhang, Y. (2023) · Autophagy · doi:10.1080/15548627.2023.2261758 · Cited by 92 · see citing works

Malaria and artemisinin derivatives: an updated review

Ansari, M. T., Saify, Z. S., Sultana, N., Ahmad, I. N., Saeed-ul-Hassan, S., Tariq, I., & Khanum, M. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575113136660097 · Cited by 89 · see citing works

Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury

Liu, J., Luo, R., Zhang, Y., & Li, X. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0222 · Cited by 83 · see citing works

Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

Baghaei, K., Mazhari, S., Tokhanbigli, S., Parsamanesh, G., Alavifard, H., Schaafsma, D., & Ghavami, S. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.012 · Cited by 82 · see citing works

Artesunate alleviates hepatic fibrosis induced by multiple pathogenic factors and inflammation through the inhibition of LPS/TLR4/NF-κB signaling pathway in rats

Lai, L., Chen, Y., Tian, X., Li, X., Zhang, X., Lei, J., Bi, Y., Fang, B., & Song, X. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.040 · Cited by 80 · see citing works

Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy

Zhang, C., Liu, S., & Yang, M. J. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i2.180 · Cited by 71 · see citing works

Artesunate improves glucose and lipid metabolism in db/db mice by regulating the metabolic profile and the MAPK/PI3K/Akt signalling pathway

Chen, L., Wang, J., Ren, Y., Ma, Y., Liu, J., Jiang, H., & Liu, C. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155382 · Cited by 70 · see citing works

Artesunate, as a HSP70 ATPase activity inhibitor, induces apoptosis in breast cancer cells

Pirali, M., Taheri, M., Zarei, S., Majidi, M., & Ghafouri, H. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.08.198 · Cited by 69 · see citing works

Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells

Weifeng, T., Feng, S., Xiangji, L., Su, C., Zhiquan, Q., Huazhong, Z., Peining, Y., Yong, Y., Wu, M., Xiaoqing, J., et al. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.07.003 · Cited by 69 · see citing works

IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study

Kao, J., Feng, C., Yu, C., Tsai, S.-M., Hsu, P., Chen, Y.-L., & Wu, Y. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0283-5 · Cited by 65 · see citing works

Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy

(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64 · see citing works

The Emerging Role of Ferroptosis in Liver Diseases

Chen, S., Zhu, J., Zang, X., & Zhai, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.801365 · Cited by 63 · see citing works

Sox9/INHBB axis-mediated crosstalk between the hepatoma and hepatic stellate cells promotes the metastasis of hepatocellular carcinoma

Chen, Y., Qian, B., Sun, X., Kang, Z., Huang, Z. K., Ding, Z., Dong, L., Chen, J., Zhang, J., & Zang, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.025 · Cited by 53 · see citing works

Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma

Ilamathi, M., Santhosh, S., & Venkatabalasubramanian, S. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160212122820 · Cited by 53 · see citing works

Artesunate induces ROS-dependent apoptosis via a Bax-mediated intrinsic pathway in Huh-7 and Hep3B cells

Pang, Y., Qin, G., Wu, L., Wang, X., & Chen, T. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.06.012 · Cited by 52 · see citing works

Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment

Stella, L., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i21.2251 · Cited by 52 · see citing works

Artesunate may inhibit liver fibrosis via the FAK/Akt/β-catenin pathway in LX-2 cells

Lv, J., Bai, R., Wang, L., Gao, J., & Zhang, H. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0255-9 · Cited by 47 · see citing works

Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling

Li, Y., Lü, J., Chen, Q., Han, S., Shao, H., Chen, P., Jin, Q., Yang, M., Shangguan, F., Fei, M., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02579-3 · Cited by 47 · see citing works

Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling

Su, T., Li, F., Guan, J., Liu, L., Huang, P. C., Wang, Y., Qi, X., Liu, Z., Lu, L., & Wang, D. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152968 · Cited by 47 · see citing works

Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjogren’s syndrome

Xiao, F., Rui, K., Han, M., Zou, L., Huang, E., Tian, J., Zhang, L., Jiang, Q., Wu, Y., & Lu, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01103-x · Cited by 46 · see citing works

Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling

Ilamathi, M., Prabu, P. C., Ayyappa, K. A., & Venkatabalasubramanian, S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.061 · Cited by 43 · see citing works

Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis

Guo, X., Asthana, P., Zhai, L., Cheng, K. W., Gurung, S., Huang, J., Wu, J., Zhang, Y., Mahato, A. K., Saarma, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45452-3 · Cited by 41 · see citing works

Artesunate ameliorates hepatic fibrosis induced by bovine serum albumin in rats through regulating matrix metalloproteinases

Xu, Y., Liu, W., Fang, B., Gao, S., & Yan, J. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.035 · Cited by 41 · see citing works

Cirrhosis Regression in Patients With Viral Hepatitis B and C

Manne, V., Akhtar, E., & Saab, S. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000162 · Cited by 40 · see citing works

Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer

Chen, Y., Yang, J.-R., Wang, C., Wang, T., Zeng, Y., Li, X., Zuo, Y., Chen, H., Zhang, C., Cao, Y., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03133-5 · Cited by 39 · see citing works

Intravenous Artesunate for the Treatment of Severe Imported Malaria: Implementation, Efficacy, and Safety in 1391 Patients

Roussel, C., Ndour, P. A., Kendjo, É., Larréché, S., Taieb, A., Henry, B., Lebrun‐Vignes, B., Chambrion, C., Argy, N., Houzé, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab133 · Cited by 38 · see citing works

Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis

Chen, Y.-X., Lai, L.-N., Zhang, H.-Y., Bi, Y.-H., Li, M., Li, X.-J., Tian, X.-X., Wang, L.-M., Fan, Y., Zhao, Z.-F., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i10.2949 · Cited by 37 · see citing works

Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation

Chen, W., Ma, Z., Yu, L., Mao, X., Ma, N., Guo, X., Yin, X., Jiang, F., Wang, Q., Wang, J., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00780-6 · Cited by 36 · see citing works

Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma

Wu, J., Liu, S., Xing, Y., Mu, M., Zhao, R., Xie, J., & Hu, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.115 · Cited by 35 · see citing works

Antimalarial agent artesunate protects Concanavalin A-induced autoimmune hepatitis in mice by inhibiting inflammatory responses

Zhao, X., Liu, M., Li, J., Yin, S., Wu, Y., & Wang, A. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.07.012 · Cited by 34 · see citing works

Artesunate induces ER-derived-ROS-mediated cell death by disrupting labile iron pool and iron redistribution in hepatocellular carcinoma cells.

Jiang, Z., Wang, Z., Chen, L., Zhang, C., Liao, F., Wang, Y., Wang, Y., Luo, P., Luo, M., & Shi, C. (2021) · PubMed Central · Cited by 34 · see citing works

Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT

Zhang, J., Zhou, L., Xiang, J., Jin, C., Li, M., & He, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107705 · Cited by 34 · see citing works

The interrupted cross-talk of inflammatory and oxidative stress trajectories signifies the effect of artesunate against hepatic ischemia/reperfusion-induced inflammasomopathy

Ghoneim, M. E.-S., Abdallah, D. M., Shebl, A. M., & El-Abhar, H. S. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115309 · Cited by 34 · see citing works

Artesunate protects against surgery-induced knee arthrofibrosis by activating Beclin-1-mediated autophagy via inhibition of mTOR signaling

Wan, Q., Chen, H., Xiong, G., Jiao, R., Liu, Y., Li, X., Sun, Y. L., Wang, J., & Yan, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.017 · Cited by 33 · see citing works

Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery

Kim, D. B., Lee, D. K., Cheon, C., Ribeiro, R. I. M. D. A., & Kim, B. (2022) · Nutrients · doi:10.3390/nu14204252 · Cited by 31 · see citing works

Artesunate induces melanoma cell ferroptosis and augments antitumor immunity through targeting Ido1

Liu, W., Zhou, H., Lai, W., Hu, C., Wang, Q., Yuan, C., Luo, C., Yang, M., Hu, M., Zhang, R., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01759-8 · Cited by 31 · see citing works

Liver cirrhosis: molecular mechanisms and therapeutic interventions

Dong, Z., Wang, Y., & Jin, W. (2024) · MedComm · doi:10.1002/mco2.721 · Cited by 31 · see citing works

Hepatitis B Virus Core Variants, Liver Fibrosis, and Hepatocellular Carcinoma

Ligat, G., Schuster, C., & Baumert, T. F. (2018) · Hepatology · doi:10.1002/hep.30231 · Cited by 30 · see citing works

Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma , decompensation and mortality

Lee, S. W., Huang, D. Q., Bettencourt, R., Ajmera, V. H., Tincopa, M. A., Noureddin, N., Amangurbanova, M., Siddiqi, H., Madamba, E. V., Majzoub, A. M., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17783 · Cited by 29 · see citing works

Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth

Li, H., Xu, K., Pian, G., & Sun, S. (2019) · Oncology Letters · doi:10.3892/ol.2019.10810 · Cited by 29 · see citing works

Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival

Pinyopornpanish, K., Al-Yaman, W. A., Dasarathy, S., Romero‐Marrero, C., & McCullough, A. J. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07048-5 · Cited by 27 · see citing works

Recent progress in the effect of ferroptosis of HSCs on the development of liver fibrosis

Tang, R., Luo, J., Zhu, X., Miao, P.-Y., Tang, H., Jian, Y., Ruan, S.-B., Ling, F.-Q., & Tang, M.-X. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1258870 · Cited by 27 · see citing works

Artesunate Induces Ferroptosis in Hepatic Stellate Cells and Alleviates Liver Fibrosis via the ROCK1/ATF3 Axis

Wang, Y., Li, Y., Qiu, Y., Shen, M., Wang, L., Shao, J., Zhang, F., Xu, X., Zhang, Z., Guo, M. L., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00162 · Cited by 27 · see citing works

Expression of p53 in the Effects of Artesunate on Induction of Apoptosis and Inhibition of Proliferation in Rat Primary Hepatic Stellate Cells

Longxi, P., Bu-wu, F., Yuan, W., & Gao, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026500 · Cited by 25 · see citing works

Synergetic delivery of artesunate and isosorbide 5-mononitrate with reduction-sensitive polymer nanoparticles for ovarian cancer chemotherapy

Li, G., Ling, M., Yu, K., Yang, W., Liu, Q., He, L., Cai, X., Zhong, M., Mai, Z., Sun, R., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01676-3 · Cited by 25 · see citing works

HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site

Zhang, D., Zhang, K., Protzer, U., & Zeng, C. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00062 · Cited by 24 · see citing works

The Translational Bridge between Inflammation and Hepatocarcinogenesis

Gufler, S., Seeboeck, R., Schatz, C., & Haybaeck, J. (2022) · Cells · doi:10.3390/cells11030533 · Cited by 24 · see citing works

Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing Ferroptosis through inhibiting the AKT/mTOR signaling

Xia, Y., Tang, Y., Huang, Z., Ke, N., Zheng, Y., Zhuang, W., Zhang, Y., Yin, X., Tu, M., Chen, J., et al. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111108 · Cited by 24 · see citing works

Dosing ribavirin in hepatitis E-infected solid organ transplant recipients

de Winter, B. C. M., Hesselink, D. A., & Kamar, N. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.030 · Cited by 24 · see citing works

Current Perspectives on the Unique Roles of Exosomes in Drug Resistance of Hepatocellular Carcinoma

Xue, D., Han, J., Liang, Z., Jia, L., Liu, Y., Tuo, H., & Peng, Y. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s351038 · Cited by 23 · see citing works

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells

He, W., Huang, X., Berges, B. K., Wang, Y., An, N., Su, R., & Lu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.615889 · Cited by 21 · see citing works

Artesunate acts as fuel to fire in sensitizing HepG2 cells towards TRAIL mediated apoptosis via STAT3 inhibition and DR4 augmentation

Ilamathi, M., & Venkatabalasubramanian, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.086 · Cited by 21 · see citing works

Artesunate, an anti-malarial drug, has a potential to inhibit HCV replication

Dai, R.-J., Xiao, X., Peng, F., Li, M., & Gong, G. (2016) · Virus Genes · doi:10.1007/s11262-015-1285-7 · Cited by 20 · see citing works

Modulation of the HIF-1α-NCOA4-FTH1 Signaling Axis Regulating Ferroptosis-induced Hepatic Stellate Cell Senescence to Explore the Anti-hepatic Fibrosis Mechanism of Curcumol

Zheng, Y., Wang, L., Wang, J., Zhao, T., & Wang, J. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673271261231213051410 · Cited by 20 · see citing works

IL-17a promotes hepatocellular carcinoma by increasing FAP expression in hepatic stellate cells via activation of the STAT3 signaling pathway

Sun, D., Li, W., Ding, D., Tan, K., Ding, W., Wang, Z., Fu, S., Hou, G., Zhou, W., & Gu, F. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01995-4 · Cited by 20 · see citing works

Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HB eAg‐positive high viral load chronic hepatitis B

Nam, J. Y., Chang, Y. W., Cho, H., Kang, S. H., Cho, Y. Y., Cho, E. J., Lee, J., Yu, S. J., Yoon, J., & Kim, Y. J. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12838 · Cited by 19 · see citing works

Artesunate alleviates schistosomiasis-induced liver fibrosis by downregulation of mitochondrial complex Ⅰ subunit NDUFB8 and complex Ⅲ subunit UQCRC2 in hepatic stellate cells

Shen, S., Luo, J., & Ye, J. (2020) · Acta Tropica · doi:10.1016/j.actatropica.2020.105781 · Cited by 18 · see citing works

The role of inflammasome in chronic viral hepatitis

Wan, P., Yang, G., Cheng, Q., Zhang, X., Yue, Z., Li, M., Liu, C., Qian, Y., Jia, Y., Liu, J., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1382029 · Cited by 17 · see citing works

Role of Artesunate in Autoimmune Diseases and Signaling Pathways

Gu, J., Xu, Y., Hua, D., & Chen, Z. (2023) · Immunotherapy · doi:10.2217/imt-2023-0052 · Cited by 16 · see citing works

Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation

Tang, J., Zhang, J., Zhang, G., Peng, W., Ling, N., Zhou, Y., Xu, H., Ren, H., & Chen, M. (2024) · mBio · doi:10.1128/mbio.03068-23 · Cited by 16 · see citing works

Artesunate Inhibits Lipid Accumulation and Inflammation by Regulating the NLRP3 Inflammasome in Nonalcoholic Fatty Liver Disease

Sun, J., Chen, C., & Wang, J. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436181.36 · Cited by 13 · see citing works

Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences

Boulahtouf, Z., Virzì, A., Baumert, T. F., Verrier, E. R., & Lupberger, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052787 · Cited by 12 · see citing works

A review of Phyllanthus urinaria L. in the treatment of liver disease: viral hepatitis, liver fibrosis/cirrhosis and hepatocellular carcinoma

Liu, L., Wang, B., Ma, Y., Sun, K., Wang, P., Li, M., Dong, J., Qin, M., Li, M., Wei, C., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1443667 · Cited by 11 · see citing works

Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus

Bhise, N., Agarwal, M., Thakur, N., Akshay, P. S., Cherian, S., & Lole, K. S. (2023) · Archives of Virology · doi:10.1007/s00705-023-05770-1 · Cited by 11 · see citing works

Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment

Li, Z.-B., Chen, D., Jia, Y., He, Q., Cui, L., Du, F.-X., Kang, Y., Feng, X., He, M. L., Jin, X., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1413589 · Cited by 8 · see citing works

Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong

Chow, V. Y. S., & Cheung, W. I. (2024) · BMC Gastroenterology · doi:10.1186/s12876-023-03099-2 · Cited by 6 · see citing works

Review article: the management of hepatitis A, B, D and non‐A non‐B

Dusheiko, G. M. (1989) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1989.tb00186.x · Cited by 6 · see citing works

Mining host candidate regulators of schistosomiasis-induced liver fibrosis in response to artesunate therapy through transcriptomics approach

Yuan, Y., Lv, X., Wu, Y., Weng, Y., Dai, F., Ding, H., Chen, R., Zheng, B., Zhao, W., Tong, Q., et al. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011626 · Cited by 5 · see citing works

[Exploring the effects of artesunate and fuzheng huayu decoction on mitochondria in the treatment of schistosomiasis liver fibrosis].

Luo, J. T., Qian, S. N., Wu, K. Y., Zhu, S. C., Huang, Y., Ye, J. P., & Shen, S. (2022) · PubMed · doi:10.3760/cma.j.cn501113-20201024-00577 · Cited by 4 · see citing works

Validation of the Texas Hepatocellular Carcinoma Risk Index Predictive Model for Hepatocellular Carcinoma in Asian Cohort

Yoo, J., Song, Y.-G., Moon, J. E., Kim, Y. S., & Kim, S. G. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.028 · Cited by 4 · see citing works

Artesunate Inhibits Anti-Liver Fibrosis by Blocking the Epithelial-Mesenchymal Transition and Regulating the c-Jun N-Terminal Kinase Pathway

Pan, C., Li, L., & Li, G. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1050 · Cited by 1 · see citing works

High incidence of hepatocarcinoma in patients with advanced fibrosis treated with direct-acting antiviral agents for hepatitis C: A real-world retrospective study

Oliveira, M., Gaspar, R., Santos, L., & Macedo, G. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102404 · Cited by 1 · see citing works

Editorial: Precision medicine in viral hepatitis: progress and prospects towards elimination

Fernández‐Rodríguez, A., & Valva, P. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1378423 · Cited by 1 · see citing works

Natural anti-cancer products: insights from herbal medicine

Cui, D., Zhang, C., Zhang, L., Zheng, J., Wang, J., He, L., Jin, H., Kang, Q., Zhang, Y., Li, N., et al. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01124-y · Cited by 59 · see citing works

Artesunate Nanoplatform Targets the Serine–MAPK Axis in Cancer‐Associated Fibroblasts to Reverse Photothermal Resistance in Triple‐Negative Breast Cancer

Zheng, D., Yan, J., Liu, X., Zhang, Z., Jin, A., Zhao, Y., Bai, L., Quan, M.-Y., Qi, X., Fu, B., et al. (2025) · Advanced Materials · doi:10.1002/adma.202502617 · Cited by 34 · see citing works

m6A methylation dependent autophagy activation is required for anti-tumor effects of artesunate through ferroptosis in hepatocellular carcinoma

Li, Y., Shen, M., Li, M., Qiu, Y., Wang, Y. L., Shao, J., Xuan, J., Zheng, S., & Zhang, Z. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.111950 · Cited by 7 · see citing works

The Role of Artesunate in Cancer Management: Mechanisms of Biomedical Effects and Toxicology

Li, J. F., Zheng, J., Cui, Y., Liu, Y., Fan, H., Wang, X., Liu, H., Li, X., Yu, G., & Luo, Z. (2025) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x25500922 · Cited by 6 · see citing works

Artesunate regulates malignant progression of breast cancer cells via lncRNA TUG1/miR-145-5p/HOXA5 axis

Yang, C., Liu, Y., Gai, L., Zhang, Z., Zhang, Y., Zhang, G., Du, K., & Gao, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329490 · Cited by 5 · see citing works

Traditional Chinese Medicine Monomers and Their Derivatives as a Promising Therapeutic Tool for Hepatocellular Carcinoma by Activation of Mitophagy

Zhu, J., Yin, S., Luo, S., Yu, F., & Sun, K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s535244 · Cited by 4 · see citing works

MnUA–DOX–artesunate hydrogel remodels immunosuppressive tumor microenvironment and prevents postoperative recurrence in triple-negative breast cancer

Cai, K., Xia, R., Xu, M., Chen, W., Cai, W., Liu, X., Guo, T., Jiang, W., Yu, C., Feng, J., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04381-7 · Cited by 4 · see citing works

Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells

Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2 · see citing works

Global research status and frontiers on ferroptosis in hepatocellular carcinoma: a comprehensive bibliometric and visualized analysis

Zhu, J., Luo, S., Yu, F., & Sun, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1549600 · Cited by 2 · see citing works

Artesunate reduces oxidative stress and inflammation in NAFLD by activating the Nrf2 pathway

Meng, Q., Zhong, M., Zhao, J., Xu, H., Jiang, W., Lin, C., Karishma, G., Wang, F., Xu, F., & Li, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117643 · Cited by 2 · see citing works

Disruption of HSPA8-GEMIN5 interaction suppresses colorectal cancer by impaired splicing-translation coupling-mediated proteostasis imbalance

Wang, F., Huang, H., Zhang, R., Wei, X., Wang, Z., Qiu, X., Gao, Y., Wang, X., Xie, W., Zhang, H., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03645-2 · Cited by 2 · see citing works

Artesunate Ameliorates APAP‐induced Liver Injury by Promoting NEDD4L‐Mediated Ubiquitination and Degradation of TXNIP

Zhang, Z., Zhang, H., Guo, H., Zhang, X., Wang, Y., Wang, B., Wang, T., Zhao, G., Zhang, Q., Gao, F., et al. (2026) · Advanced Science · doi:10.1002/advs.202521818 · Cited by 2 · see citing works

Research Progress on the Mechanisms of Traditional Chinese Medicine in Preventing and Treating HCC Invasion and Metastasis Based on Lipid Metabolic Reprogramming

Wang, M., Lyu, H., Liu, Y., & Sun, Y. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266366687250730060318 · Cited by 1 · see citing works

Targeted ferroptosis of myofibroblasts by tubeimoside I attenuates hypertrophic scar formation

Wang, J., Wang, C., Jia, Y., Chen, F., Wang, Y., & Du, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1654108 · Cited by 1 · see citing works

Hyaluronan-mediated motility receptor regulating the Wnt/β-catenin signaling resulting in hepatocellular carcinoma by inhibiting the phosphorylation activity of GSK-3β

Zhang, Y., Zhang, Z., Yan, Z., He, M., & Wang, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-03372-y · Cited by 1 · see citing works

The Therapeutic Effects of Active Components from Food-Medicine Plants on Liver Fibrosis

Sun, C., Chen, B., Hu, Y., Wang, S., Chen, T., Xu, M., & Gong, Q. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s573983 · Cited by 1 · see citing works

Artesunate nanoliposomes in hepatocellular carcinoma: mechanistic ferroptosis induction and translational opportunities

Zhao, C., Wang, L., Xia, C., Ma, P., Huang, B., Dong, G., Shi, Y., & Zeng, S. (2026) · Discover Oncology · doi:10.1007/s12672-025-04267-4 · Cited by 1 · see citing works

Artesunate attenuates sepsis-induced myocardial injury: A preliminary investigation into the JAK2/STAT3 pathway via integrated network pharmacology and experimental validation

Li, T. Z., Lv, Y., Zhang, J., Rui, H., Ma, X., Wang, J., Jiang, Y., Yuan, Y., Meng, Y., Ma, X., et al. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154048 · Cited by 1 · see citing works

Artesunate as an emerging anticancer modality: Insights and advances

Petrlak, F., Jemelikova, V., Hanzlíková, A., Šlesingerová, T., Haddad, Y., Opsenica, I., Taniele‐Silva, J., & Rodrigo, M. Á. M. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108317 · Cited by 1 · see citing works

Artesunate attenuates pulmonary fibrosis by suppressing fibroblast senescence through inhibition of the STAT3/p53 signaling pathway

Ding, J., Chen, Z., Yu, J., Xu, Y., Zhu, T., Wang, B., Feng, Z., Li, X., Qian, X., Jin, B., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117646

A gene signature associated with alpha-linolenic acid metabolism predicts clinical prognosis in hepatocellular carcinoma

Shi, Q., Hu, X., & Wu, Z. (2026) · European journal of medical research · doi:10.1186/s40001-025-03762-2

A telomere-based prognostic model incorporating E2F1, MYCN, VPS72, CFAP53, OR8A1, and TXNRD1 for hepatocellular carcinoma

Wang, Y., Fu, L., Yang, Z., Wang, W., Sun, J., & Gu, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-03900-4

Combination of artesunate and ruxolitinib suppresses T cell leukemia/lymphoma proliferation via the JAK STAT pathway

Yuan, Y., Li, Y., Li, J., Wang, S., Luo, F., Huang, C., Yang, J., Hu, Y., Jia, Y., & Wang, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-39393-8

Artesunate ameliorates experimental autoimmune uveitis by inhibiting the LCN2-STAT3 axis and suppressing microglial activation

Gu, J., Xia, Q., Huang, P., Yuan, Y., Ren, H., Hua, D., & Chen, Z. (2026) · Redox Report · doi:10.1080/13510002.2026.2627096

Traditional Chinese medicine-mediated ferroptosis in cancer therapy: mechanisms, advances, and nanotechnology-driven delivery strategies

Wei, L., Liu, T., Ma, Y., Li, J., & Qian, H. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101156

Artesunate suppresses nasopharyngeal carcinoma progression by directly targeting MMP2

Wang, X., Huang, W., & Huang, S. (2026) · Applied Biological Chemistry · doi:10.1186/s13765-026-01087-0

Targeting sirtuins in diabetic retinopathy: Differential roles in inflammation and mitochondrial dysfunction

Pan, C.-C., Xie, Q.-Q., Lu, P.-Y., Shi, Z., Li, H., Ma, Y.-J., Ding, T.-Y., Zeng, M.-Q., Luo, C., & Zhuge, F. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i4.116208

Artesunate Induces G0 / G1 Phase Arrest in Tumor Cells and Associates With Cyclin‐Dependent Kinase 4 ( CDK4 )

Chi, X., Chen, Q., Wang, G., Luo, H., Qu, S., & Zou, X. (2026) · Cancer Medicine · doi:10.1002/cam4.71907

Neocryptomerin targets NAE1 to induce DNA re-replication and DNA damage by inhibiting neddylation-mediated CDT1 degradation in gastric cancer

Tan, P., Fu, D., Wang, F., Wang, Z., Huang, H., Wei, X., Qiu, X., Gao, Y., Zhang, R., Wang, X., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108255

Targeting SEC23A: Artesunate's dual pathway approach to reversing gastric metaplasia

Hu, Q., Wu, F., Zhang, Y., Zeng, L., Chen, J., Ma, Y., Ma, X., Zeng, J., & Zhao, Y. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101667

Artesunate-based macromolecular therapy attenuates neutrophilic asthma by targeting the BCAT1/Succinate/NLRP3 metabolite-immunity cascade

Gong, J., Zhou, M. M., Huang, Y., Yu, M., Zhou, Q., Chen, S. S., Wang, J., Yang, M., Luo, Q., Zhang, R., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04749-9

Rational design and synthesis of TBC1D2 inhibitors: Augmenting autophagy to improve sorafenib sensitivity in hepatocellular carcinoma

Han, K., Lin, Y., Huang, Y.-J., Tang, Y., Pu, J., Zhang, L., Wang, L., & Zhu, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119124

Natural products mediate ferroptosis and immune microenvironment-linked sensitization in osteosarcoma: from chemotherapy resistance to combined therapeutic transformation

Dai, Y., & Ding, W. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11707-y

Investigation of the in vitro time-dependent effects of artesunate and benznidazole on Leishmania tropica

Özel, Y., Dogan, G., & Çavuş, İ. (2026) · European Journal of Life Sciences · doi:10.55971/ejls.1898193

Artesunate in Ferroptosis and Cuproptosis Regulation: Context-Dependent Mechanisms, Interplay, and Therapeutic Implications

Feng, K., Xia, Y., Liu, J., & Yang, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177862

Inter- and intramolecular photoactivation of artemisinin and derivatives by xanthone-based triplet and singlet sensitizers

van Stiphoudt, J. F. W. F. W., Bold, C., & Griesbeck, A. G. (2026) · Organic & Biomolecular Chemistry · doi:10.1039/d6ob01142j

3,4-dehydro-3‑hydroxy-α-lapachone, a novel naphthoquinone, ameliorates hepatic fibrosis by targeting the guanine nucleotide-binding protein G(i) subunit alpha-2/peroxiredoxin 1 signaling axis

Zhang, W., Xu, L.-H., Gao, K., Girimpuhwe, D., Ren, H., Xu, D., Yang, G.-G., Luo, X.-W., Wang, J., & Wu, Q. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158879

Artesunate targets STAT3 to alleviate Hodgkin’s lymphoma via JAK-STAT/PD-L1 axis

Chen, D., Zhang, G., San, J., Liu, B., Yuan, P., & Ren, M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118571

Artemisinin in chronic liver disease: therapeutic potential and mechanistic insights

Cheng, F.-E., Zheng, S., 杜宏波, & Ye, Y. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.101033

Inhibition of hepatocellular carcinoma progression by artesunate via modulation of the TLR4/MyD88/NF-κB signaling pathway

Wu, Y., Wu, J., Li, Z., Wu, Z., Li, S., Yang, G., Rong, X., Wang, Q., Li, Y., Xia, Q., et al. (2025) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2025-95 · Cited by 5 · see citing works

Therapeutic effects of artesunate in hepatocellular carcinoma

Vandewynckel, Y., Laukens, D., Geerts, A. M., Vanhove, C., Descamps, B., Colle, I. O., Devisscher, L., Bogaerts, E., Paridaens, A., Verhelst, X., et al. (2014) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000066 · Cited by 43 · see citing works

Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway

Kong, Z., Liu, R., & Cheng, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.030 · Cited by 364 · see citing works

Artesunate directly targeting MMP9 to reduce angiogenesis and increase CD8 + T cell infiltration inhibits hepatocellular carcinoma

Wang, N., Yao, L., Dong, X., Man, X.-H., Liu, B., Li, H., Sun, J., Jiang, R., Guo, M., Bi, J., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04323-1 · Cited by 1 · see citing works

Artesunate nanoliposomes in hepatocellular carcinoma: mechanistic ferroptosis induction and translational opportunities

Zhao, C., Wang, L., Xia, C., Ma, P., Huang, B., Dong, G., Shi, Y., & Zeng, S. (2026) · Discover Oncology · doi:10.1007/s12672-025-04267-4 · Cited by 1 · see citing works